Pharma BD Deal Intelligence
Abbott Laboratories / Genentech Inc. (Roche Group)
2007 · Co-Development · Complete
Announcement Sentiment
90
Strongly positive
Global co-development of ABT-263 (Bcl-2 antagonist, navitoclax) and ABT-869. Financial terms undisclosed. Source: Fierce Biotech, PharmaTimes.
Key facts
- Announced Jun 19, 2007
- Deal type Co-Development
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals